Clinical Trials Logo
  1. Home
  2. Corona Virus Infection
  3. NCT04686760
  4. Details
NCT04686760 Clinical Trial

Efficacy of Inhaled Nitroglycerin in Moderate to Critically Ill COVID-19 Patients

Corona Virus Infection Clinical Trial

Official title:
Efficacy of Inhaled Nitroglycerin in Moderate to Severe Cases of COVID-19 Patients

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT04686760
Other study ID # IRBEC/BIH/08-2020
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 15, 2020
Est. completion date March 15, 2022

Study information
Verified date May 2022
Source University of Lahore
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In current analysis moderate to severely ill Covid-19 infected patients will be nebulized with nitroglycerin, and they will be compared with the standard nebulization

Recruitment information / eligibility
Status Completed
Enrollment 278
Est. completion date March 15, 2022
Est. primary completion date December 15, 2021
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: Diagnosed admitted cases of Covid-19 degree of illness should be moderate to severe both male and female every age group Exclusion Criteria: allergic to nitroglycerin sudden drop in blood pressure not given consent

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• Nitroglycerin
2 mg/ml solution of nitroglycerin used for nebulization four hourly

Locations
Country Name City State
Pakistan Bahria Town International Hospital Lahore Punjab

Sponsors (1)
Lead Sponsor Collaborator
University of Lahore

Country where clinical trial is conducted

Pakistan, 

Outcome
Type Measure Description Time frame Safety issue
Primary ratio of partial pressure of oxygen in arterial blood to fraction of inhaled oxygen 5-7 days
Primary Oxygen demand 5-7 days
Secondary Duration of hospital stay 15 days
See also
  Status Clinical Trial Phase
Completed NCT04384445 - Zofin (Organicell Flow) for Patients With COVID-19 Phase 1/Phase 2
Completed NCT04578210 - Safety Infusion of NatuRal KillEr celLs or MEmory T Cells as Adoptive Therapy in COVID-19 pnEumonia or Lymphopenia Phase 1/Phase 2
Completed NCT05065827 - Lung Ultrasound Findings in Patients With COVID-19 in a UK ED
Completed NCT04720794 - A Study To Evaluate The Performance of the Lucira Health All-In-One COVID-19 Test Kit vs Hologic Panther Fusion N/A
Enrolling by invitation NCT04659486 - Adolescents With COVID-19/MIS-C at HCFMUSP N/A
Completed NCT04598620 - Non-invasive Prognostication of COVID-19 Patients by Use of Biomarkers in Exhaled Breath Condensate
Completed NCT05517941 - Effect of Active Cycle Breathing Technique Along With Incentive Spirometer on COVID19 Patient N/A
Recruiting NCT04480333 - Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831 Phase 1
Recruiting NCT04565782 - Corona Virus Infection Among Liver Transplant Recipients
Active, not recruiting NCT04558476 - Efficacy of CONvalescent Plasma in Patients With COVID-19 Treated With Mechanical Ventilation Phase 2
Completed NCT04526769 - Detecting SARS-CoV-2 in Tears
Completed NCT05639998 - BBV152/BBV154 Heterologus Prime-Boost Study Phase 2
Completed NCT05736926 - Anal Fissure Among Survivors of COVID-19 Virus Infection.
Completed NCT04523246 - Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents Early Phase 1
Withdrawn NCT04386447 - Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19 Phase 2
Recruiting NCT04583566 - Differential Expression of Cytokines, Transcriptome and miRNA in Coronavirus Disease 2019 (COVID-19) Egyptian's Patients
Completed NCT04643678 - Anakinra in the Management of COVID-19 Infection Phase 2/Phase 3
Recruiting NCT04579588 - Understanding Immunity to the Flu Vaccine in COVID-19 Patients
Terminated NCT03331445 - Inhaled Gaseous Nitric Oxide (gNO) Antimicrobial Treatment of Difficult Bacterial and Viral Lung (COVID-19) Infections Phase 2
Recruiting NCT04573348 - T Cells Response to SARS COV 2 Peptides